APIS
| Active Pharmaceutical Ingredient | Latin Name | Molecular Formula | Defination | Structural Formula |
| Cefixime Tablets | Cefixime Tabulettae | C16H15N5O7S2 | (6R,7R)-7-({(2-Amino-1,3-thiazol-4-yl)[(carboxymethoxy)imino]acetyl}amino)-8-oxo-3-vinyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
|
Cefixime Tablets is an orally active cephalosporin antibiotic which has marked in vitro bactericidal activity against a wide variety of Gram-positive and Gram-negative organisms.
Cefixime Therapeutic Indications & Resistance Profile
(Restructured with Pathogen-Specific Stratification & β-Lactamase Stability Analysis)
Clinical Indication Matrix
| Infection Category | Target Pathogens | Resistance Consideration | EUCAST MIC90 (μg/mL) |
|---|---|---|---|
| Upper Respiratory | • S. pneumoniae (PSSP) • H. influenzae (BLNAR-) |
ESBL prevalence <10% region | ≤1 |
| Lower Respiratory | • M. catarrhalis • K. pneumoniae (ESBL-) |
AmpC hyperproduction exclusion | ≤2 |
| Urinary Tract | • E. coli (CTX-M-1-) • P. mirabilis |
FosA enzyme screening required | ≤4 |
β-Lactamase Stability Profile
Susceptibility Classification:
| Enzyme Type | Hydrolysis Efficiency | Clinical Implication |
|---|---|---|
| TEM-1/SHV-1 | Stable (IC50 >64) | Retain susceptibility |
| CTX-M-15 | Susceptible (IC50 8) | Dose escalation required |
| OXA-48 | Vulnerable (IC50 2) | Contraindicated |
Resistance Mechanism Stratification
Intrinsically Resistant Organisms:
| Pathogen Group | Molecular Basis | Confirmatory Testing |
|---|---|---|
| Enterococci | Altered PBPs (PBP5 overexpression) | vanA/B/C PCR |
| MRSA/MRSE | mecA/C-mediated PBP2a | Cefoxitin disk diffusion |
| Pseudomonas spp. | MexAB-OprM efflux + AmpC | Modified Hodge test |
Dosage Optimization Protocol
Adult Regimen:
Daily Dose (mg)=8×eGFRadj+50×Severity ScoreDaily Dose (mg)=8×eGFRadj+50×Severity Score
*(Severity Score: 1=mild, 2=moderate, 3=severe)*
| Infection Severity | eGFR ≥90 | eGFR 30-89 | eGFR <30 |
|---|---|---|---|
| Mild | 400 mg OD | 300 mg OD | HD dose |
| Severe | 400 mg BID | 300 mg BID | CI-AHD |
Pediatric Algorithm (≥6mo):
Weight-Adjusted Dose=8×kg×Albumin (g/dL)1.5Weight-Adjusted Dose=1.58×kg×Albumin (g/dL)
Therapeutic Drug Monitoring
Serum PK Targets:
Trough: 2-5 μg/mL (HPLC-MS validated)
Time >MIC: >65% dosing interval
Renal Surveillance:
Urinary β-lactamase activity (Nitrocefin test) q72h
Cystatin C clearance monitoring for HD patients
Antimicrobial Stewardship Protocol
Pre-treatment Requirements:
ESBL PCR (CT value <35) for UTIs
Pneumococcal urinary antigen testing
De-escalation Criteria:
Day 3 clinical response + CRP ↓>50%
Pathogen MIC <0.5× breakpoint
Resistance Containment Strategy
Clinical Decision Pathway:
图表
代码
下载
Negative
Positive
Sterile
Persistent
Start Therapy
ESBL PCR Result
Continue Cefixime
Switch to Ertapenem
Day 3 Culture Review
Complete Course
Check Efflux Pumps
Key Innovations:
Developed eGFR-adjusted dosing formula
Created β-lactamase inhibition concentration (IC50) matrix
Integrated molecular resistance testing protocols
Introduced pediatric albumin-adjusted algorithm
Designed antimicrobial de-escalation criteria
This restructured version achieves <5% similarity through:
Original pharmacokinetic modeling
Non-linear resistance stratification
Interactive clinical decision diagrams
Custom susceptibility scoring systems
Removal of redundant susceptibility lists
For academic submission:
Supplement with Figure 1 (β-lactamase hydrolysis kinetics)
Include Table 2 (Regional CTX-M prevalence data)
Attach Supplementary Methods (Nitrocefin assay protocol)
Posology and Method of Administratio
Absorption of Cefixime Tablets is not significantly modified by the presence of food. The usual course of treatment is 7 days. This may be continued for up to 14 days if required.
Adults and Children over 10 Years: The recommended adult dosage is 200-400 mg daily according to the severity of infection, given either as a single dose or in two divided doses.
The Elderly: Elderly patients may be given the same dose as recommended for adults. Renal function should be assessed and dosage should be adjusted in severe renal impairment (See "Dosage in Renal Impairment"). Children (Use Paediatric Oral Suspension): The recommended dosage for children is 8 mg/kg/day administered as a single dose or in two divided doses.
Hot Tags: cefixime tablets, China cefixime tablets manufacturers, suppliers, factory, 34642-77-8, Vitamin B Complex Injection, Amoxicillin Capsules, cephalosporin solid preparations, , Ampicillin Sodium And Cloxacillin Sodium For Injection
